Longer lives, bigger profits: Why I’m bullish on GlaxoSmithKline plc, McCarthy and Stone plc and Carnival plc

Will adding GlaxoSmithKline (LON:GSK), McCarthy and Stone (LON:MCS) and Carnival (LON:CCL) give vitality to your portfolio?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Life expectancy has grown rapidly over recent decades. This is a good thing for us, of course, and it may also be good for our investments. Today, I’ll be looking at three companies that are likely to benefit most.

In need of a health kick?

People will always need medicine, especially as populations (particularly in developing markets) continue to grow and as developed world citizens live longer. With this in mind, adding a pharmaceutical giant to your portfolio may be a shrewd move.

GlaxoSmithKline (LSE:GSK) seems as good a candidate as any. Shares have disappointed over the last few years, dipping to 1,237p last September as a result of concerns surrounding the loss of profit-generating patents. Things now seem to be on the mend. The forthcoming departure of CEO Sir Andrew Witty and some positive figures in the April’s Q1 earnings release has led analysts to start re-evaluating the company and its future prospects.

Glaxo’s share currently trade at 1,410p. While not screamingly cheap with a P/E ratio of 16, the accompanying 80p per share dividend is a fairly decent sticking plaster for now. Although there have been concerns about Glaxo’s ability to cover this payout, these should abate if the company can prove it’s still on the road to recovery when it announces its Q2 results at the end of July.

Time to build a position?

Shares in retirement homes builder, McCarthy and Stone (LSE:MCS) have dropped rather heavily since their peak of 287p in January, perhaps more as a result of general market jitters and the forthcoming EU referendum than anything to do with the company itself. Indeed, the firm’s first set of half-year results since returning to the market last August certainly gave investors reason for cheer.

Reporting a 33% rise in revenue, Chairman John Wright commented that the group had made “strong progress” towards its goal of building and selling more than 3,000 properties every year. Underlying profit before tax increased by 23% to £39.1m with legal completions up by 19% to 923 units. A 1p interim dividend may sound miserly compared to huge payouts offered by other housebuilders, but this dividend is expected to rise rapidly to 6.78p in 2017, covered over three times by earnings.

Having a 70% share in this niche market gives McCarthy and Stone a dominant position over competitors, something that may become even more apparent as a greater proportion of baby boomers downsize. A 26% jump in the order book from £243m to £306m in one year would appear to back this up.

Calm waters ahead 

The imminent maiden voyage of the gigantic Harmony of the Seas cruise liner has made headlines this week. Cruises have appealed to those in retirement but the fact that people are now far more active in their senior years, and given that it’s the fastest growing sector of the global tourism industry, would suggest companies like Carnival (LSE:CCL) will benefit massively now and in the future.

According to Stockopedia, the £27bn cap has a PEG ratio of 0.89 for the current year. Experienced investors will know that anything under 1 signals they’re getting a lot of growth for their money. A dividend yield of just under 2.5%, while fairly average for a mature FTSE100 company, indicates the board is confident of profits being on a steady course.

Paul Summers owns shares in GlaxoSmithKline and McCarthy and Stone.  The Motley Fool has recommended shares in GlaxoSmithKline.  We fools don’t all hold the same views but we all believe that considering a diverse range of insights makes us better investors.

 

More on Investing Articles

Happy woman commuting on a train and checking her mobile phone while using headphones
Investing For Beginners

Is this the biggest bargain in the FTSE 100 right now?

Jon Smith reviews a FTSE 100 stock that's fallen by 18% so far this year that he believes could be…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

Will Rolls-Royce shares soar to £17.40 or sink to 900p?

Rolls-Royce shares have surged almost 90% in value over the last 12 months. Can the FTSE 100 company repeat the…

Read more »

A quiet morning and an empty Victoria Street in Edinburgh's historic Old Town.
Investing Articles

£10,000 invested in Scottish Mortgage shares 5 weeks ago is now worth…

Why have Scottish Mortgage shares displayed resilience in the FTSE 100 index since the war in Iran started a few…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

How can I target £14,132 a year in dividend income from a £20,000 holding in this FTSE 250 dividend gem?

This FTSE 250 dividend heavyweight keeps generating market-beating yields, with forecasts of more to come as earnings momentum continues to…

Read more »

Nottingham Giltbrook Exterior
Investing Articles

Marks and Spencer’s share price is down 16% to below £4! Is now the time for me to buy the dip with an eye to £8+?

Marks and Spencer’s share price has dipped, but is the market missing a far bigger story? The latest numbers hint…

Read more »

Young female hand showing five fingers.
Investing Articles

5 dividend shares that ISA millionaires love

These wealthy investors seem to prioritise blue-chip dividend shares that offer both stability and attractive levels of income.

Read more »

Exterior of BT Group head office - One Braham, London
Investing Articles

£10,000 invested in BT shares 5 years ago has turned into…

BT shares have underperformed the FTSE 100 over the past five years. James Beard looks at the reasons why and…

Read more »

Emma Raducanu for Vodafone billboard animation at Piccadilly Circus, London
Investing Articles

£5,000 invested in Vodafone shares 5 years ago is now worth…

Vodafone’s shares have underperformed the FTSE 100 since April 2021. However, this isn’t the full story. James Beard explains why.

Read more »